Abstract
BackgroundPancreatic cancer has significant morbidity and mortality worldwide. Good prognosis relies on an early diagnosis. The purpose of this study was to develop techniques for identifying cancer biomarkers in the serum of patients with pancreatic cancer.MethodsSerum samples from five individuals with pancreatic cancer and five individuals without cancer were compared. Highly abundant serum proteins were depleted by immuno-affinity column. Differential protein analysis was performed using 2-dimensional differential in-gel electrophoresis (2D-DIGE).ResultsAmong these protein spots, we found that 16 protein spots were differently expressed between the two mixtures; 8 of these were up-regulated and 8 were down-regulated in cancer. Mass spectrometry and database searching allowed the identification of the proteins corresponding to the gel spots. Up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2, which have not previously been implicated in pancreatic cancer, were observed. In an independent series of serum samples from 16 patients with pancreatic cancer and 16 non-cancer-bearing controls, increased levels of mannose-binding lectin 2 and myosin light chain kinase 2 were confirmed by western blot.ConclusionsThese results suggest that affinity column enrichment and DIGE can be used to identify proteins differentially expressed in serum from pancreatic cancer patients. These two proteins 'mannose-binding lectin 2 and myosin light chain kinase 2' might be potential biomarkers for the diagnosis of the pancreatic cancer.
Highlights
Pancreatic cancer has significant morbidity and mortality worldwide
The results indicated that protein spots (1158, 805, 800, 779 and 574) had the protein mass fingerprints (PMF) and the corresponding proteins could be identified (Table 2)
In the present study, we carried out DIGE proteomics analysis on sera from pancreatic cancer patients and its cancer-free controls
Summary
Pancreatic cancer has significant morbidity and mortality worldwide. Good prognosis relies on an early diagnosis. Extensive efforts have been focused on finding candidates for serum tumor markers and many candidates have been listed, none of them has yet been proven to be clinically useful These tumor markers are neither tumor-specific nor pancreatic cancer-specific. CA19-9 is the most widely used tumor marker in pancreatic cancer, the specificity is low It may be elevated in benign conditions including pancreatitis, hepatitis and cirrhosis, as well as in gastric cancer and colon cancer [8,9,10]. Other markers such as CEA, CA125 are being studied, but not for the diagnosis of pancreatic cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
